Market research
EX1.AU Exopharm Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.44
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU0000030975
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.44
About
About Exopharm Limited
Tryp Therapeutics Inc., a clinical-stage pharmaceutical development company, focuses on developing psilocybin-related molecules in Canada and the United States. Its lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2a clinical trial for the treatment of binge eating disorder, fibromyalgia, abdominal pain, and visceral tenderness. The company's program candidate TRP-8802, a synthetic and oral psilocybin for the treatment of binge eating, chronic pain, and other indications. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EX1.AU discussion.
5 years, 5 months ago
Exopharm Limited is currently in a long term downtrend where the price is trading 6.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Exopharm Limited's total revenue sank by 92.1% to $3K since the same quarter in the previous year.
Its net income has dropped by 58.3% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 9.7% to $-2M since the same quarter in the previous year.
Based on the above factors, Exopharm Limited gets an overall score of 2/5.